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1. Introduction
It is well established that pregnancy complications and adverse birth outcomes are impor-
tant public health concerns in both developed and developing countries. Prenatal develop-
ment refers to the process in which an embryo and later fetus develop during gestation. Each 
pregnancy can be divided into three trimesters of approximately 3 months each. A normal, 
full-term pregnancy lasts about 40 weeks. During the 40 weeks of pregnancy, the embryo and 
fetus are heavily influenced by environment (Figure 1).
The human placenta is the highly specialized organ of pregnancy that is responsible normal 
fetal growth and development [1]. It plays an important role in substance exchange between the 
Figure 1. The embryo and fetus are heavily influenced by environment during the 40 weeks of pregnancy.
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mother and the fetus during pregnancy. Many chemicals can transfer across the placenta and 
influence the development of the embryo and fetus [2]. The fetus is unable to detoxify substances 
efficiently because of their weak capability to detoxify toxic chemicals. Additionally, there are 
many different factors which can cause abnormalities of the placenta, such as environmental risk 
factors [3], genetic risk factors [4], and epigenetic risk factors [5]. Several studies have demon-
strated that placental disorders are associated with pregnancy complications and adverse birth 
outcomes, including gestational diabetes mellitus (GDM), preeclampsia, miscarriage, preterm 
birth, stillbirth, macrosomia, and fetal growth restriction (FGR) [6–9]. The cause of pregnancy 
complications and adverse birth outcomes remains largely unknown but accumulating evidence 
have proved that environmental risk factors, genetic risk factors, and epigenetic risk factors may 
play important roles in the etiology and susceptibility of these diseases (Figure 2).
The pathogenesis of adverse pregnancy and birth outcomes is multifactorial, involving com-
plex interactions between environmental influences, genetics, and epigenetic mechanisms. 
This introductory chapter mainly discusses the evidence linking several kinds of risk factors 
and adverse pregnancy and birth outcomes, such as environmental risk factors, genetic risk 
factors, and epigenetic risk factors.
2. Environmental impacts on prenatal development
The environment can have an important influence on fetal development. Variety of chemicals 
have been reported to be present in urine, blood, and amniotic fluid, which indicated that preg-
nant women around the world are highly exposed to chemicals [10–12]. Additionally, several 
studies also have shown that a wide range of chemicals has been detected in cord blood and 
fetal tissues, including bisphenol-A (BPA), phthalates, pesticides, and heavy metals [10, 13].
Environmental risk factors have a deleterious effect on prenatal development leading to prob-
lems including premature birth, stillbirth, and low birth weight [14–16]. While environmen-
tal hazards pose a definite threat to the developing fetus, they do not always cause adverse 
effects. The harmful health effect of environmental risk factors is determined by the timing of 
Figure 2. Several risk factors may affect fetal growth and development during pregnancy.
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the exposure, the dose/duration of the exposure, genetic susceptibility, and gene-environment 
interactions [17, 18]. The fetus is particularly vulnerable to environmental hazards that dis-
rupt developmental processes during relatively narrow developmental periods. For example, 
a birth cohort study of 1390 women found that arsenic concentrations in the third trimester, 
but not in the first and second trimesters, were negatively associated with birth weight and 
birth length [19]. Therefore, the timing of exposure during pregnancy is an important factor 
that may influence the outcome of exposure.
Multiple environmental risk factors, such as exposure to endocrine disrupting chemicals 
(EDCs), smoking, air pollution, can have a range of impacts on the health of a growing fetus 
[20, 21]. EDCs have the potential to interfere with endogenous hormone action. Several stud-
ies have suggested adverse endocrine disruptive effects of EDCs on the fetus, such as miscar-
riage, low birth weight, hypospadias, cryptorchidism, and other birth defects [20, 22]. For 
example, BPA is an EDC that is ubiquitous in modern environments, which provides great 
potential for exposure of the developing fetus. Links between BPA and endocrine disrup-
tion has been implicated in the etiology of several kinds of adverse reproductive outcomes 
[23, 24]. There is a large body of evidence showing that maternal smoking during pregnancy 
and secondhand smoking exposure can result in placental problems (previa and/or abrup-
tion), miscarriage, stillbirth, premature birth, and FGR [25, 26]. However, quitting smoking 
(even during pregnancy) greatly reduces the risks of these problems [25].
Although a large number of studies have examined the association between environmen-
tal risk factors exposure during pregnancy and adverse pregnancy and birth outcomes, the 
molecular mechanism of environment-induced adverse pregnancy and birth outcomes is still 
not fully understood. Thus, further researches are needed to investigate the molecular mecha-
nisms underlying environment-induced adverse pregnancy and birth outcomes.
3. Genetic risk factors and pregnancy complications and adverse 
birth outcomes
It has been estimated that single nucleotide polymorphisms constitute approximately 90% 
of all genetic variations in the human populations. Over the past few decades, a number 
of epidemiologic studies, using both the candidate gene and genome-wide approach, have 
examined associations between genetic variants and the risk of pregnancy complications and 
adverse birth outcomes, such as GDM, preeclampsia, preterm birth, small for gestational age, 
and birth defects [18, 27–30]. Several genetic loci in genes have been identified to be associated 
with risks of pregnancy complications and adverse birth outcomes [27–29].
Several studies have found that gene polymorphism plays important roles in the susceptibil-
ity of pregnancy complications and adverse birth outcomes. A study conducted in the SCOPE 
pregnancy cohort found that the maternal and infant FTO (rs9939609) polymorphism AA 
genotype was significantly associated with increased risk of small for gestational age preg-
nancy and spontaneous preterm birth [31]. In a meta-analysis, Zhang et al. identified that 
nine polymorphisms in seven genes involved in the regulation of insulin secretion were sig-
nificantly associated with risk of GDM. Among the nine polymorphisms, the rs7903146 in 
Introductory Chapter: Environmental, Genetic, and Epigenetic Risk Factors in Adverse Pregnancy…
http://dx.doi.org/10.5772/intechopen.76902
3
TCF7L2 showed the strongest association with risk of GDM [27]. The MTHFR C677T poly-
morphism as a common genetic cause for hyperhomocysteinemia was associated with hyper-
tension in pregnancy, preterm birth, and low birth weight [32, 33]. Nurk et al. examined the 
association between two polymorphisms of MTHFR gene (677C > T and 1298A > C) and preg-
nancy complications, adverse outcomes, and birth defects in 5883 women of the Hordaland 
Homocysteine Study. They found that the maternal carriage of the MTHFR 677C > T poly-
morphism was associated with the risk of placental abruption. However, they did not find 
significant associations between MTHFR polymorphisms and birth defects [34].
Though a large number of epidemiologic studies have examined the association between 
gene polymorphisms and adverse pregnancy and birth outcomes, a large portion of the 
results are inconsistent. Therefore, future studies with larger sample size, genomic-wide asso-
ciation studies (GWAS), and large-scale replications of identified associations are needed to 
illustrate the most significant genetic variants that associated with risk of adverse pregnancy 
and birth outcomes. Furthermore, as the genetic association of a polymorphism with adverse 
pregnancy and birth outcomes does not equate to a casual role, functional analysis should be 
performed to identify the causal variants.
4. Epigenetics and adverse pregnancy and birth outcomes
In addition to the sequence of the genome, the contribution of epigenetics to adverse preg-
nancy and birth outcomes is increasingly recognized. Epigenetics refers to heritable changes 
in gene expression patterns which do not alter DNA sequence. Epigenetics is now recognized 
as playing an important role in the etiology of human disease [7, 35, 36]. The main epigenetic 
mechanisms responsible for adverse pregnancy and birth outcomes are represented by DNA 
methylation, histone modifications, and noncoding RNA [37].
A growing body of evidence demonstrates that aberrant epigenetic modifications are asso-
ciated with adverse pregnancy and birth outcomes [9, 38]. Using 1030 placental samples, 
Reichetzeder and colleagues reported that global placental DNA methylation was signifi-
cantly increased in women with GDM [9]. In the study by Côté et al., maternal glycemia at 
the second and third trimester of pregnancy is correlated with variations in DNA methylation 
levels at PRDM16, BMP7, and PPARGC1α and with cord blood leptin levels [38].
The epigenetic signature inherited from the gametes is erased and established after fertiliza-
tion [39]. The requirement of a high degree of spatial-temporal coordination of epigenetic 
changes during this process provides opportunities for disruption by environmental chem-
icals [40]. Unlike inherited genetic variation that is static through the course of a lifetime, 
epigenetic changes are sensitive indicators of the effects of acute and chronic environmental 
exposure [41]. Epigenetic mechanisms have been shown to be influenced by environmental 
factors. Abnormal epigenetic modifications represent an important mechanism for environ-
mental factors influencing the risk of adverse pregnancy and birth outcomes. Exposure to 
EDCs during pregnancy has been shown to influence epigenetic programming of endocrine 
signaling and other important physiological pathways, thus further disrupt normal fetal 
development [42, 43]. The low-dose BPA administration to pregnant mice has been found to 
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cause hypomethylation at NotI loci that is involved in brain development [44]. Recent animal 
study has reported that prenatal exposure to di-n-butyl phthalate (DBP) can lead to marked 
changes in the epigenetic regulation of gene expression [45].
Previous studies have demonstrated that prenatal exposure to some EDCs (such as vinclo-
zolin, methoxychlor, DBP, and DDT) may cause the transgenerational effect of adult disease 
[45, 46]. In recent years, a growing body of research has spotlighted the role of epigenetic 
mechanism in the transgenerational effect of prenatal exposure to EDCs [45–47]. Many of the 
environmentally induced epigenetic changes can be transmitted to future generations and 
associated with disease phenotypes in the unexposed individuals of subsequent generations. 
It has been reported that prenatal exposure to DBP may have the transgenerational effect 
of spermatogenic failure [45]. These adverse outcomes were accompanied by global DNA 
hypomethylation and spermatogenesis modulator gene (Fstl3) promoter hypomethylation, 
suggesting that prenatal DBP exposure can be imprinted through epigenetic alterations. 
Additionally, epigenetic markers may be useful as biomarkers for environmental exposure 
and disease and as potential targets for preventive and therapeutic interventions [48, 49].
This chapter puts an updated overview of the risk factors of adverse pregnancy outcomes and 
birth outcomes, transgenerational effect of prenatal environmental exposure on health in later 
life, and epigenetic mechanisms of environmental risk factor-induced adverse pregnancy out-
comes and birth outcomes. By this way, these observations can be used to advise pregnant 
women or women of reproductive age to avoid such exposures and adopt a positive lifestyle 
to protect pregnancy and normal fetal development. Overall, avoidance of potential risk fac-
tors, identification of high susceptible women, and provision of personalized medical care are 
important in the healthcare management of pregnant women.
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